Skip to main content
Diabetes patients willing to use adjunct therapies, study finds
5/24/2019

Researchers used a cohort of 1,313 adults with type 1 diabetes, median age of 53, and found that 93% would consider using an adjunct therapy of 200 mg or 400 mg sotagliflozin, with the 400-mg dose as the preferred option, compared with taking insulin alone. The findings in Diabetes Technology & Therapeutics revealed that maintaining A1C levels within a target range, making diabetes management less stressful and keeping daytime blood glucose levels between 70 mg/dL and 180 mg/dL were among the unmet needs considered high priority among patients.

Full Story: